Athenex Inc (ATNX) Director Jinn Wu Buys 10,000 Shares

Athenex Inc (NASDAQ:ATNX) Director Jinn Wu acquired 10,000 shares of the firm’s stock in a transaction dated Monday, March 26th. The shares were purchased at an average price of $14.66 per share, for a total transaction of $146,600.00. Following the completion of the transaction, the director now directly owns 259,208 shares in the company, valued at $3,799,989.28. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jinn Wu also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Friday, February 9th, Jinn Wu purchased 10,000 shares of Athenex stock. The stock was bought at an average price of $13.64 per share, for a total transaction of $136,400.00.

Shares of Athenex Inc (NASDAQ ATNX) traded down $0.88 during midday trading on Monday, reaching $15.32. 829,103 shares of the company’s stock were exchanged, compared to its average volume of 388,795. Athenex Inc has a one year low of $11.21 and a one year high of $20.79.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. grew its stake in shares of Athenex by 253.0% in the 4th quarter. BlackRock Inc. now owns 1,086,985 shares of the company’s stock worth $17,282,000 after buying an additional 779,092 shares in the last quarter. Greenleaf Trust grew its stake in shares of Athenex by 19.1% in the 4th quarter. Greenleaf Trust now owns 556,670 shares of the company’s stock worth $8,851,000 after buying an additional 89,089 shares in the last quarter. Prince Street Capital Management LLC purchased a new position in shares of Athenex in the 4th quarter worth $2,798,000. Geode Capital Management LLC grew its stake in shares of Athenex by 29.8% in the 4th quarter. Geode Capital Management LLC now owns 116,809 shares of the company’s stock worth $1,857,000 after buying an additional 26,833 shares in the last quarter. Finally, Jaffetilchin Investment Partners LLC purchased a new position in shares of Athenex in the 4th quarter worth $1,711,000. Institutional investors own 5.95% of the company’s stock.

A number of brokerages have issued reports on ATNX. Zacks Investment Research downgraded shares of Athenex from a “buy” rating to a “hold” rating in a report on Thursday. Needham & Company LLC began coverage on shares of Athenex in a report on Tuesday, March 6th. They issued a “buy” rating and a $30.00 price target on the stock. BidaskClub upgraded shares of Athenex from a “sell” rating to a “hold” rating in a report on Thursday, January 18th. JPMorgan Chase & Co. lifted their price target on shares of Athenex from $22.20 to $23.00 and gave the company a “neutral” rating in a report on Wednesday, January 24th. Finally, Deutsche Bank set a $20.00 price target on shares of Athenex and gave the company a “buy” rating in a report on Wednesday, January 17th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Athenex has an average rating of “Buy” and an average price target of $26.86.

COPYRIGHT VIOLATION WARNING: This piece was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3303250/athenex-inc-atnx-director-jinn-wu-buys-10000-shares.html.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Insider Buying and Selling by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

TriMas  Releases FY18 Earnings Guidance
TriMas Releases FY18 Earnings Guidance
Analyzing Liberty Tax Service  & Its Peers
Analyzing Liberty Tax Service & Its Peers
Contrasting Ituran  & Arrow Electronics
Contrasting Ituran & Arrow Electronics
Constellium  vs. Aqua Metals  Head-To-Head Survey
Constellium vs. Aqua Metals Head-To-Head Survey
Brokerages Anticipate Sorrento Therapeutics  Will Announce Earnings of -$0.17 Per Share
Brokerages Anticipate Sorrento Therapeutics Will Announce Earnings of -$0.17 Per Share
Aditus  Price Down 10.6% Over Last 24 Hours
Aditus Price Down 10.6% Over Last 24 Hours


© 2006-2018 Ticker Report. Google+.